Analystreport

Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its price target lowered by analysts at Chardan Capital from $146.00 to $121.00.

Intellia Therapeutics, Inc.  (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview